Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : DNDN - Dendreon Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Elmer who wrote (74)	10/25/2000 12:45:50 AM
From: brk	Respond to of 751

Oh yeah....I'm hiding under my desk tomorrow. :)

To: Elmer who wrote (74)	11/7/2000 11:37:52 AM
From: brk	Read Replies (1) \| Respond to of 751

Dendreon Opens Cell Processing Center; New Center in Hackensack, NJ Supports Ongoing Phase III Trials for Provenge Business Editors, Health/Medical Writers SEATTLE--(BW HealthWire)--Nov. 7, 2000--Dendreon Corporation (Nasdaq:DNDN) today announced it has expanded its cell processing capabilities with the opening of a new center in conjunction with Progenitor Cell Therapy, L.L.C., in Hackensack, NJ. At the new center, Progenitor Cell Therapy will prepare Provenge(TM), Dendreon's therapeutic vaccine for the treatment of prostate cancer, and Mylovenge(TM), Dendreon's therapeutic vaccine for multiple myeloma. The center employs Dendreon's proprietary technology to prepare vaccines utilizing specialized immune cells, called dendritic cells. "This center will provide important support for clinical sites and patients on the East Coast participating in our current Phase III trials of Provenge and our expanding trials of Mylovenge," said Frank Valone, M.D., chief medical officer, Dendreon Corporation. Dendreon's immunotherapy programs are now supported in the U.S. by five cell processing centers. The other centers are located at Dendreon's company headquarters in Seattle, Wash. and satellite office in Mountain View, Calif.; the Mayo Clinic in Rochester, Minn.; and the American Red Cross in Philadelphia, Pa. A cell processing center in Tokyo, Japan is operated in conjunction with Kirin Brewery Co., Ltd. Dendreon Corporation (www.dendreon.com) is dedicated to the discovery and development of novel products for the treatment of cancer through its innovative manipulation of the immune system. Dendreon is focused on the development of therapeutic cancer vaccines through the use of antigen discovery, antigen engineering and dendritic cell technologies. Dendreon's vaccine for the treatment of prostate cancer, Provenge(TM), is in Phase III clinical trials and its vaccine for the treatment of multiple myeloma, Mylovenge(TM), is in Phase II clinical trials. Progenitor Cell Therapy, L.L.C. is a commercial cell engineering company that provides for the collection, manufacture, storage and redistribution of human cells for therapeutic purposes through a nationwide network, operated in compliance with current Good Manufacturing Practices. Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties that may cause actual results to differ materially from the results discussed in the forward-looking statements, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such a difference include risks related to Dendreon's limited operating history, risks associated with completing our clinical trials, dependence on the efforts of third parties, and our dependence on intellectual property. Further information on the factors and risks that could affect Dendreon's business, financial condition and results of operations, are contained in Dendreon's SEC Reports, including Dendreon's Form 10-Q and Form S-1 Registration Statement, No. 333-47706, which are available at www.sec.gov. 3005 First Avenue, Seattle, Washington 98121 206/256-4545 Fax - 206/256-0571 www.dendreon.com --30--ATR/se* CONTACT: for Dendreon Communications/Investor Relations Julie Rathbun, 206/256-4545 ext. 1500 jrathbun@dendreon.com